Discontinued — last reported Q3 '24
Labcorp Holdings Drug Development — Percent of Revenue Contributed remained flat by 0.0% to 22.0% in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 4.3%, from 23.0% to 22.0%.
An increase suggests the company is becoming more reliant on pharmaceutical R&D spending, while a decrease indicates a greater focus on core clinical diagnostic testing.
This metric represents the proportion of total consolidated revenue generated by the drug development and clinical resea...
Similar to revenue mix metrics for diversified healthcare companies that operate both diagnostic labs and CRO services.
lh_segment_drug_development_percent_of_revenue_contributed| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 39% | 36% | 37% | 39% | 39% | 37% | 23% | 23% | 22% | 22% | 22% |
| QoQ Change | — | -7.7% | +2.8% | +5.4% | +0.0% | -5.1% | -37.8% | +0.0% | -4.3% | +0.0% | +0.0% |
| YoY Change | — | — | — | +0.0% | +8.3% | +0.0% | -41.0% | -41.0% | -40.5% | -4.3% | -4.3% |